Meeting
2017 ASCO Annual Meeting
Inhibition of autophagy sensitizes gastrointestinal stromal tumor cells to TKI/Bcl-2 inhibitors-induced apoptosis.
Authors
Shuchao Zhang
University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
Shuchao Zhang , Guozhi HU , Ana Cristina Paz-Mejia , Luyuan Li , Jonathan C. Trent II
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11036)
DOI
10.1200/JCO.2017.35.15_suppl.11036
Abstract #
11036
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).
First Author: Haibo Qiu
Poster
2016 ASCO Annual Meeting
Efficacy of BLU-285, a novel, potent inhibitor of Exon 17 Mutant KIT and PDGFRA D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST).
First Author: Yemarshet Kelemework Gebreyohannes
Poster
2013 ASCO Annual Meeting
In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).
First Author: Cesar Serrano-Garcia
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick